AKT1 and cancer: Next, we studied the response of the cancer cell models upon treatment with a panel of seven drugs targeting a broad range of mechanisms and pathways, i.e., the DNA synthesis inhibitors 5-FU and doxorubicin, mitosis-inhibiting alisertib and paclitaxel, the PI3K/AKT/mTOR inhibitor torin2, as well as cisplatin and olaparib which target the DNA damage response (DDR) pathway (Fig. 3g).